Wednesday, January 23, 2019
JPMorgan downgrades Apellis to Neutral with no data until Q4
JPMorgan analyst Anupam Rama downgraded Apellis Pharmaceuticals to Neutral from Overweight with an unchanged price target of $34. The analyst continues to like the shares long term and view APL-2 as an underappreciated asset in the complement space. However, with data not out until Q4, the analyst expects Apellis shares to perform in line with the market in the first half of 2019.
https://thefly.com/landingPageNews.php?id=2852307
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.